ArticleCancer management and research2010
Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.
Article in Cancer management and research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.Breast cancer research and treatment · 2012Trial
- Signal mining and safety profile analysis of lapatinib: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database.Journal of pharmaceutical policy and practice · 2026Article
- Integrative proteo-genomic profiling uncovers key biomarkers of lapatinib resistance in HER2-positive breast cancer.British journal of cancer · 2025Article
- EGFR is a potential dual molecular target for cancer and Alzheimer's disease.Frontiers in pharmacology · 2023Review
- Inhibition of mutationally activated HER2.Chemical biology & drug design · 2023Article
- Using X-ray Diffraction Techniques for Biomimetic Drug Development, Formulation, and Polymorphic Characterization.Biomimetics (Basel, Switzerland) · 2020Review
- Evaluating Trastuzumab in the treatment of HER2 positive breast cancer.Histology and histopathology · 2020Review
- Attenuation of p53 mutant as an approach for treatment Her2-positive cancer.Cell death discovery · 2020Review
- Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.Therapeutic advances in medical oncology · 2018Article
- Analysis of in vitro ADCC and clinical response to trastuzumab: possible relevance of FcγRIIIA/FcγRIIA gene polymorphisms and HER-2 expression levels on breast cancer cell lines.Journal of translational medicine · 2015Article
- Expression of eag1 channel associated with the aggressive clinicopathological features and subtype of breast cancer.International journal of clinical and experimental pathology · 2015Article
- Tyrosine kinase inhibitors as reversal agents for ABC transporter mediated drug resistance.Molecules (Basel, Switzerland) · 2014Review
- Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions.World journal of clinical oncology · 2014Review
- Neurotoxicity of biologically targeted agents in pediatric cancer trials.Pediatric neurology · 2012Review
- Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.Cancer control : journal of the Moffitt Cancer CenterArticle
- Targeted therapeutic options and future perspectives for HER2-positive breast cancer.Signal transduction and targeted therapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lapatinib is a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). EGFR and HER2 overexpression is associated with aggressive breast cancer with a high risk of disease relapse and death. Although lapatinib targets both EGFR and HER2, its effects on HER2 appear to be more critical. The role of lapatinib in the first-line setting remains unclear. A phase II first-line monotherapy lapatinib trial in HER2-therapy-naïve metastatic breast cancer (MBC) patients confirms efficacy in HER2-positive tumors. Retrospective analysis of a phase III, first-line MBC study confirmed incremental benefit from lapatinib and paclitaxel over paclitaxel alone in HER2-positive disease. A prospective phase III study confirms superiority of letrozole and lapatinib over letrozole alone in HER2-positive MBC. Further investigation is required to define the potential first-line role for lapatinib. Particular strengths appear to be its manageable toxicity profile, lack of cross resistance with trastuzumab, activity in central nervous system disease, and synergy in combination with other anticancer therapy. Current limitations are lack of dosing recommendations from early trials, lack of predictive biomarkers beyond HER2 status, and lack of large prospective phase III trials for HER2-positive disease in the first-line setting. The role of lapatinib in HER2-negative disease is unclear.
Indexed as
Identifiers
21188093PMC3004582W1728803387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.